Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by bligickaon Nov 01, 2020 3:28pm
101 Views
Post# 31820460

RE:RE:RE:RE:RE:Preclinical data, Monday or Tuesday.

RE:RE:RE:RE:RE:Preclinical data, Monday or Tuesday.Ya I'm not arguing with you either.....let's wait till Tuesday and see how the market reacts to David Hagin's data....also nice to know we could also see the results of the Army's trial in a very short period of time as well !!
silentrunning wrote: Blig, I'm not disagreeing nor arguing with you about this. From the info we've received, the deal was made between USAMRIID and VXL. VXL is paying USAMRIID to verify the tech is solid. From my understanding the results will be released pending good, not good, maybe etc. Best to you All
bligicka wrote: Results from David Hagin's trial should be enough to prove Phase 1 worthiness in my opinion !!!
silentrunning wrote: The verification of our "peptide technology" by USAMRIID has got to be the *ultimate* verification/ endorsement & when we get those results back (hopefully very positive).....should propel VXL to incredible new valuations. Stay Well Be Safe






<< Previous
Bullboard Posts
Next >>